Summary
Edwards Lifesciences Corporation reported solid financial performance for the first quarter of 2026, demonstrating robust revenue growth and improved profitability. Net sales increased by 16.7% year-over-year, driven by strong demand in both Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) segments. The company also saw significant growth in its Surgical products. Despite increased operating expenses, particularly in R&D and SG&A to support future growth, the company managed to improve its net income. A notable event during the quarter was the acquisition of Autus Valve Technologies, Inc., which is expected to bolster the company's pipeline in pediatric valve solutions. Investors should note the ongoing legal proceedings, particularly concerning tax matters, which represent a potential area of volatility, although management believes current accruals are adequate. The company also continued its aggressive share repurchase program, indicating confidence in its financial health and commitment to returning value to shareholders.
Financial Highlights
49 data points| Revenue | $1.65B |
| Cost of Revenue | $362.60M |
| Gross Profit | $1.29B |
| R&D Expenses | $263.30M |
| SG&A Expenses | $522.20M |
| Operating Income | $477.60M |
| Net Income | $380.70M |
| EPS (Basic) | $0.66 |
| EPS (Diluted) | $0.66 |
| Shares Outstanding (Basic) | 579.20M |
| Shares Outstanding (Diluted) | 580.70M |
Key Highlights
- 1Net sales increased by 16.7% to $1.65 billion in Q1 2026 compared to Q1 2025, driven by strong performance in TAVR (up 14.4%) and TMTT (up 51.9%).
- 2Acquisition of Autus Valve Technologies for $128.9 million completed in February 2026, adding a pediatric valve technology to its portfolio.
- 3Gross profit margin decreased slightly due to foreign currency fluctuations and increased manufacturing expenses for new therapies, despite overall sales growth.
- 4Diluted earnings per share increased to $0.66 in Q1 2026 from $0.61 in Q1 2025, reflecting improved operational performance.
- 5Research and Development expenses increased, indicating continued investment in innovation, particularly in heart failure management and advanced technologies.
- 6The company repurchased approximately 4.9 million shares for $520.1 million in Q1 2026 as part of its ongoing share repurchase program.
- 7Significant legal and tax matters are ongoing, including a large IRS transfer pricing dispute, though management believes current accruals are adequate.